Company intelligence / Profile preview

Biotyx Medical

Shenzhen, Guangdong, Chinapitchbook.com ↗

Ownership: Private
Development stage: Commercial

Overview

Biotyx Medical has developed the world’s first iron-based bioabsorbable material technology platform, with its lead product, the IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System, having completed clinical enrollment in a China prospective multicenter single-arm target study. Preliminary clinical data have shown advantages of these devices. Other products are in pre-registration clinical stages in China.

Therapeutic areas: Cardiovascular
Modalities: DeviceIron-based bioabsorbable vascular scaffoldStent (biodegradable)
Industry: Implantable Medical Devices

Drug pipeline

3 assets

IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

Phase 3

Indications: Coronary artery stenosis

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Biotyx Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotyx Medical.

Explore the full profile